Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer

Nature Chemical Biology

Volumn 9, Issue 10, 2013, Pages 643-650

  Kim, Woojin ^a,b,c   Bird, Gregory H ^b,c   Neff, Tobias ^d   Guo, Guoji ^a,b,c   Kerenyi, Marc A ^a,b,c   Walensky, Loren D ^a,b,c   Orkin, Stuart H ^a,b,c,e  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; EMBRYONIC ECTODERM DEVELOPMENT PROTEIN; POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION FACTOR EZH2;

ALPHA HELIX; ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER GROWTH; CELL VIABILITY; DOSE RESPONSE; ENZYME ACTIVE SITE; EPIGENETICS; HUMAN; HUMAN CELL; LEUKEMIA CELL; MONOCYTE MACROPHAGE PRECURSOR CELL; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY;

ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LEUKEMIA; MODELS, MOLECULAR; PEPTIDES; POLYCOMB REPRESSIVE COMPLEX 2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84884532954     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1331     Document Type: Article

References (51)

1. Cao, R. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298, 1039-1043 (2002).
2. Czermin, B. et al. Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell 111, 185-196 (2002).
3. Müller, J. et al. Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell 111, 197-208 (2002).
4. Kuzmichev, A. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev. 16, 2893-2905 (2002).
5. Varambally, S. et al. The Polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629 (2002).
6. Kleer, C.G. et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. USA 100, 11606-11611 (2003).
7. He, L-R. et al. High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int. J. Cancer 127, 138-147 (2010).
8. Wang, C. et al. EZH2 mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. Cancer Res. 72, 315-324 (2012).
9. Yu, J. et al. Integrative genomics analysis reveals silencing of β-adrenergic signaling by Polycomb in prostate cancer. Cancer Cell 12, 419-431 (2007).
10. Kong, D. et al. Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS ONE 7, e33729 (2012).
11. Varambally, S. et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322, 1695-1699 (2008).
12. Morin, R.D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181-185 (2010).
13. McCabe, M.T. et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc. Natl. Acad. Sci. USA 109, 2989-2994 (2012).
14. Béguelin, W. et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23, 677-692 (2013).
15. Fussbroich, B. et al. EZH2 depletion blocks the proliferation of colon cancer cells. PLoS ONE 6, e21651 (2011).
16. Fujii, S., Ito, K., Ito, Y. & Ochiai, A. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J. Biol. Chem. 283, 17324-17332 (2008).
17. Wilson, B.G. et al. Epigenetic antagonism between Polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 18, 316-328 (2010).
18. Chamberlain, S.J., Yee, D. & Magnuson, T. Polycomb repressive complex 2 is dispensable for maintenance of embryonic stem cell pluripotency. Stem Cells 26, 1496-1505 (2008).
19. Shen, X. et al. Jumonji modulates Polycomb activity and self-renewal versus differentiation of stem cells. Cell 139, 1303-1314 (2009).
20. Knutson, S.K. et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 8, 890-896 (2012).
21. McCabe, M.T. et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108-112 (2012).
22. Han, Z. et al. Structural basis of EZH2 recognition by EED. Structure 15, 1306-1315 (2007).
23. Neff, T. et al. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc. Natl. Acad. Sci. USA 109, 5028-5033 (2012).
24. Shi, J. et al. The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;NrasG12D acute myeloid leukemia. Oncogene doi:10.1038/onc.2012.110 (2013).
25. Walensky, L.D. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305, 1466-1470 (2004).
26. Moellering, R.E. et al. Direct inhibition of the NOTCH transcription factor complex. Nature 462, 182-188 (2009).
27. Deshayes, S., Morris, M.C., Divita, G. & Heitz, F. Cell-penetrating peptides: Tools for intracellular delivery of therapeutics. Cell. Mol. Life Sci. 62, 1839-1849 (2005).
28. Shen, X. et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol. Cell 32, 491-502 (2008).
29. Ezhkova, E. et al. EZH1 and EZH2 cogovern histone H3K27 trimethylation and are essential for hair follicle homeostasis and wound repair. Genes Dev. 25, 485-498 (2011).
30. Margueron, R. et al. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol. Cell 32, 503-518 (2008).
31. Byvoet, P., Shepherd, G.R., Hardin, J.M. & Noland, B.J. The distribution and turnover of labeled methyl groups in histone fractions of cultured mammalian cells. Arch. Biochem. Biophys. 148, 558-567 (1972).
32. Sasaki, M., Yamaguchi, J., Itatsu, K., Ikeda, H. & Nakanuma, Y. Over-expression of Polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis. J. Pathol. 215, 175-183 (2008).
33. Bracken, A.P. et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev. 21, 525-530 (2007).
34. Krivtsov, A.V. et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442, 818-822 (2006).
35. Toren, A. et al. CD133-positive hematopoietic stem cell 'stemness' genes contain many genes mutated or abnormally expressed in leukemia. Stem Cells 23, 1142-1153 (2005).
36. Suetsugu, A. et al. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem. Biophys. Res. Commun. 351, 820-824 (2006).
37. Singh, S.K. et al. Identification of human brain tumour initiating cells. Nature 432, 396-401 (2004).
38. Di Tullio, A., Vu Manh, T.P., Schubert, A., Månsson, R. & Graf, T. CCAAT/enhancer binding protein α (C/EBPα)-induced transdifferentiation of pre-B cells into macrophages involves no overt retrodifferentiation. Proc. Natl. Acad. Sci. USA 108, 17016-17021 (2011); erratum 109, 11053.
39. Pinto do, O.P. Hematopoietic progenitor/stem cells immortalized by Lhx2 generate functional hematopoietic cells in vivo. Blood 99, 3939-3946 (2002).
40. Lee, S.T. et al. Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers. Mol. Cell 43, 798-810 (2011).
41. Xu, K. et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 338, 1465-1469 (2012).
42. You, J.S & Jones, P.A. Cancer genetics and epigenetics: Two sides of the same coin? Cancer Cell 22, 9-20 (2012).
43. Hinz, S. et al. Expression of the Polycomb group protein EZH2 and its relation to outcome in patients with urothelial carcinoma of the bladder. J. Cancer Res. Clin. Oncol. 134, 331-336 (2008).
44. Tan, J. et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21, 1050-1063 (2007).
45. Momparler, R.L., Idaghdour, Y., Marquez, V.E. & Momparler, L.F. Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation. Leuk. Res. 36, 1049-1054 (2012).
46. Miranda, T.B. et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol. Cancer Ther. 8, 1579-1588 (2009).
47. Chiang, P.K. Biological effects of inhibitors of S-adenosylhomocysteine hydrolase. Pharmacol. Ther. 77, 115-134 (1998).
48. Borchardt, R.T., Keller, B.T. & Patel-Thombre, U. Neplanocin A. A potent inhibitor of S-adenosylhomocysteine hydrolase and of vaccinia virus multiplication in mouse L929 cells. J. Biol. Chem. 259, 4353-4358 (1984).
49. Bowen, N.J., Fujita, N., Kajita, M. & Wade, P.A. Mi-2/NuRD: Multiple complexes for many purposes. Biochim. Biophys. Acta 1677, 52-57 (2004).
50. Ho, L. & Crabtree, G.R. Chromatin remodelling during development. Nature 463, 474-484 (2010).
51. Chou, T-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621-681 (2006).